Phase 2 Augment 101 Study News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Phase 2 Augment 101 Study. Real-time updates on events, politics, business and more.

Revumenib Demonstrates Activity in Pediatric Patients With KMT2A+ Acute Leukemia

April 4, 2024

Phase 2 data from the AUGMENT-101 study show that revumenib elicits responses with acceptable safety in pediatric patients with KMT2A+ acute leukemia.

Zuid Holland United States C Michel Zwaan Syndax Pharmaceuticals American Society Of Pediatric Hematology Oncology Phase 2 Augment 101 Study

Source: onclive.com

Revumenib Elicits High Response Rate in R/R KMT2A-Rearranged Acute Leukemia

December 12, 2023

Revumenib demonstrated clinically meaningful activity, including high response and minimal residual disease negativity rates, in heavily pretreated patients with KMT2A-rearranged acute leukemia.

Ibrahim Aldoss City Of Hope Comprehensive Cancer Center Hope Comprehensive Cancer Center Real Time Oncology Review Acute Leukemia Kmt2a Rearranged Acute Leukemia

Source: onclive.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Phase 2 Augment 101 Study News Today

Revumenib Demonstrates Activity in Pediatric Patients With KMT2A+ Acute Leukemia

Revumenib Elicits High Response Rate in R/R KMT2A-Rearranged Acute Leukemia

Explore More Categories